Join NBTS’s campaign to raise awareness about the importance of biomarker testing and clinical trials for patients with brain tumors.
READ MOREPublished on June 7, 2017 in Press Release
Dr. Collins has been a tremendous contributor and asset to the U.S. biomedical research community throughout his career, and particularly during the more than two decades he’s served at the NIH, including the past eight as its Director.
NBTS applauds the president and administration for its decision to retain Dr. Collins in this important position as he will provide continuity, vision, expertise, and experience to this vital agency.
Additionally, we offer our congratulations to Dr. Collins and look forward to continuing to work with him and the NIH on priorities and programs that will benefit brain tumor patients.